Wyeth Reduces Risk with Dyadem Software

    TORONTO, April 2 /CNW/ -- Dyadem, the market leader in Quality Lifecycle
Management and Risk Lifecycle Management solutions, has announced that Wyeth,
a global leader in prescription pharmaceuticals and non-prescription consumer
health care products, is using software from Dyadem to enhance and standardize
its risk assessments.  Dyadem's PHA-Pro, a software solution that identifies,
measures and mitigates risk, enables Wyeth to set a new standard in safety for
its pharmaceutical products.  Wyeth's industry-leading pharmaceutical and
health care products improve lives and deliver outstanding value to customers
and shareholders by leading the world in innovation through pharmaceutical,
biotech and vaccine technologies.

    PHA-Pro is a software solution that delivers industry-standard Process
Hazard Analysis (PHA) capabilities for the process industries. The PHA
methodology is an integral part of a pharmaceutical manufacturer's Process
Safety Management program and results in safer and more predictable production
processes.  Dyadem's PHA-Pro helps manage Risk Lifecycle Management processes,
and was built to reflect the risk mitigation initiatives and operating
environments of the various process industries.  This is essential to
optimizing work time, minimizing work stoppages, and reducing the potential
for undesirable events, while improving the safety and quality of a given
product for consumers.

    With PHA-Pro being used across their global organization, Wyeth has
integrated the knowledge and expertise of all departments into their PHA
studies and provided the Environmental Health and Safety department visibility
into the overall business process, making everyone at the company more aware
of their global business and safety strategy.  "We needed a systematic,
methodical way to document our PHA studies," said Steven Meszaros, Corporate
Director, EHS (Environmental Health and Safety), Wyeth.  "With Dyadem's
PHA-Pro, Wyeth has been able to establish a community of users and a
standardized approach to our PHA studies.  It has allowed us to create a
benchmark for safety and quality for our company, which will ultimately
benefit our customers."

    Having used PHA-Pro for many years, Wyeth has been able to continuously
improve their risk management program.  The easy configuration of templates,
along with the application's industry-specific libraries and report-generating
features have allowed Wyeth to focus on their business process and overall
business strategy, instead of worrying about the consistency of their PHA
studies.  Since implementing PHA-Pro, Wyeth has been able to establish a
best-practice platform which has proven to management the value of a
consistent hazard review process across the network.

    "Wyeth's commitment to safety and visibility for all departments are some
of the reasons it has remained a leader in the pharmaceutical industry," said
Kevin North, President and CEO of Dyadem.  "Pharmaceutical companies have
traditionally had challenges ensuring consistency and accuracy in their risk
assessments, but with our Risk Lifecycle Management solutions, we have given
the industry a chance to address this.  Wyeth shows how important it is to
standardize risk mitigation initiatives, and provide an avenue for input from
all areas of a business.  Through their commitment to product safety, Wyeth
proves how easy it is to create safe, quality products and still be on the
leading edge of innovation."

    About Dyadem
    Dyadem is the market leader in Quality Lifecycle Management and Risk
Lifecycle Management solutions. Dyadem provides software and services that
empower companies to manage quality, mitigate risks, achieve regulatory
compliance, plan for business continuity and improve profitability. Dyadem
works with 85% of the Fortune 500 companies and serves the high tech &
electronics, medical devices, oil and gas, chemical, automotive,
pharmaceutical and aerospace and defense industries. For more information,
visit www.dyadem.com

    About Wyeth
    Wyeth is a global leader in prescription pharmaceuticals,
non-prescription consumer health care products, and pharmaceuticals for animal
health. Wyeth's products are sold in more than 145 countries, and its product
portfolio includes innovative treatments across a wide range of therapeutic
areas. Wyeth's worldwide resources include 47,500 employees, manufacturing
facilities on four continents, and a unique research and technology base
encompassing small molecules, biopharmaceuticals, genetic engineering that
will give us the next wave of innovative therapies, and vaccines. With this
depth of resources, Wyeth will continue to lead the way in the development of
novel therapies that address critical global health needs. For more
information, visit www.wyeth.com.


    For further information, contact:
    Text 100 Public Relations
    Kevin Doak


For further information:

For further information: Kevin Doak for Dyadem, +1-617-399-4931,
dyadem@text100.com Web Site: http://www.dyadem.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890